| |
PRZOOM - /newswire/ -
Winston-Salem, NC, United States, 2007/10/10 - SmallCapReview is introducing two new Focus Stocks, Angiotech Pharmaceuticals (Nasdaq: ANPI) and Headwaters Inc. (NYSE: HW), which we feel will out perform the market in the near-term.
|
| |
The performance of our current unbiased Focus Stocks as of Tuesday October 9, 2007 are as follows: Sirenza Microdevices introduced at $9.16, closed at $18.08. Radyne introduced at $9.04 closed at $10.72. Imax introduced at $3.99 closed at $4.72. Novatel Wireless introduced at $21.36 closed at $26.72.
Angiotech Pharmaceuticals (Nasdaq: ANPI) operates as a specialty pharmaceutical and medical device company. It discovers, develops, and markets technologies and medical products for local diseases and complications associated with medical device implants, surgical interventions, and acute injury. ANPI offers various technologies that improve the performance of medical devices and the outcomes of surgical procedures.
These technologies include various drug, drug delivery, and surface modification materials and other medical biomaterials designed to be applied across a range of medical devices and technologies, surgical procedures, and medical disciplines.
Angiotech also manufactures and markets single use, specialty medical devices, with products focused primarily on general surgery; oncology and tumor biopsy; interventional radiology and vascular surgery; ophthalmology; and aesthetic surgery.Its product candidates that are undergoing human clinical trials include TAXUS Liberte paclitaxel-eluting coronary stent system, which is related to the use of paclitaxel to prevent restenosis and other local inflammatory diseases; ZILVER PTX paclitaxel-eluting peripheral vascular stent that is designed for placement in diseased arteries in the limbs to restore blood flow; Vascular Wrap, a paclitaxel-eluting mesh surgical implant designed to treat complications associated with vascular graft implants in patients undergoing hemodialysis or have peripheral artery disease; and Anti-Infective Catheter related to central venous catheters.
Angiotech has license agreements with Boston Scientific Corporation, Cook Group Incorporated, and a distribution and license agreement with Orthovita Inc. The Company also has a manufacturing and supply agreement with Baxter Healthcare Corporation; a collaboration agreement with Genzyme Corporation and CombinatoRx Inc, and a strategic alliance agreement with Athersys Inc.
Intellectual property includes over 150 issued U.S. patents and 185 pending U.S. patent applications. The combined global company has over 1,500 employees worldwide.
Headwaters Incorporated (NYSE: HW) through its subsidiaries, provides products, technologies, and services to the energy and construction materials industries in the United States. It operates in three segments: Construction Materials, Coal Combustion Products, and Alternative Energy.
The Construction Materials segment designs, manufactures, and markets shutters, gable vents, mounting blocks, tools, and architectural manufactured stones. This segment also provides concrete blocks and other masonry units, as well as various mortars and stucco products.
The Coal Combustion Products segment markets coal combustion products, such as fly ash and bottom ash to the building products and ready mix concrete industries.
The Alternative Energy segment develops catalyst technologies to convert coal and heavy oil into liquid fuels, as well as nanocatalyst processes and applications.
Features available at SmallCapReview.com include in-depth profiles of select Small-Cap/Penny Stocks as well as the most comprehensive and up to date news available on the small-cap market.
SmallCapReview.com is not a registered investment advisor or broker/dealer. No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. Nothing within our site should be construed as an offer or solicitation to buy or sell products or securities. The companies we profile may lack an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. SmallCapReview.com may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our website or within our reports. In order to be in full compliance with the Securities Act of 1933, Section 17(b), SmallCapReview.com will disclose, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on our website. SmallCapReview has not been compensated for its efforts in presenting the Angiotech or Headwaters' profiles on its website and distributing it to its database of subscribers.
|
editor[.]smallcapreview.com 
